Holocene Advisors, LP Glaukos Corp Transaction History

Holocene Advisors, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$45.44 - $71.21 $164,810 - $258,278	3,627 New	3,627 $258,000
Q2 2022 Aug 15, 2022	SELL	$34.86 - $63.77 $967,783 - $1.77 Million	-27,762 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$44.33 - $57.82 $1.27 Million - $1.66 Million	-28,638 Reduced 50.78%	27,762 $1.61 Million
Q4 2021 Feb 14, 2022	BUY	$40.27 - $56.99 $609,728 - $862,885	15,141 Added 36.7%	56,400 $2.51 Million
Q3 2021 Nov 15, 2021	BUY	$47.43 - $84.23 $1.96 Million - $3.48 Million	41,259 New	41,259 $1.99 Million
Q4 2020 Feb 16, 2021	SELL	$48.9 - $75.26 $2.13 Million - $3.29 Million	-43,650 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$37.23 - $50.97 $596,871 - $817,151	16,032 Added 58.05%	43,650 $2.16 Million
Q2 2020 Aug 14, 2020	BUY	$28.78 - $46.83 $535,308 - $871,038	18,600 Added 206.25%	27,618 $1.06 Million
Q1 2020 May 15, 2020	BUY	$25.53 - $70.14 $230,229 - $632,522	9,018 New	9,018 $278,000
Q4 2018 Feb 14, 2019	SELL	$52.18 - $67.93 $416,761 - $542,556	-7,987 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$38.13 - $68.37 $304,544 - $546,071	7,987 New	7,987 $518,000

342

46.8M

132K

188K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.45B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Holocene Advisors, LP, based on Form 13F filings with the SEC.

Stay updated on Holocene Advisors, LP with notifications on news.